Status:
COMPLETED
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
20-80 years
Brief Summary
The purpose of this study is to asses the EED symptom prevalence in Koran GERD patients with typical reflux symptom and to evaluate quality of life with the scales including Gerd Q.
Eligibility Criteria
Inclusion
- GERD patients who have experienced heartburn or acid regurgitation during past 7 days
- GERD patients who have already undergone endoscopy before enrolment
Exclusion
- Involvement in the planning and conduct of the programme
- The person who took the medicine such as PPI or H2RA during the last 7 days
- Severe systemic disease
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2009
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT00768196
Start Date
September 1 2008
End Date
February 1 2009
Last Update
December 7 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Cheonan, Chungcheongnam-do, South Korea
2
Research Site
Seoul, Kyungkido, South Korea
3
Research Site
Sungnam, Kyungkido, South Korea
4
Research Site
Suwon, Kyungkido, South Korea